```html

Xanthopsia During Migraine Aura

What is Xanthopsia during migraine aura?

Xanthopsia is a visual disturbance in which a person sees an abnormal yellow tint over part or all of the visual field. When it occurs as part of a migraine aura, the yellow‑hued vision is usually brief (seconds to minutes) and precedes or accompanies the headache phase of a migraine attack.

In migraine aura, a wave of cortical spreading depression—a brief, self‑propagating wave of neuronal depolarisation—travels across the visual cortex. This electrical disturbance can alter colour processing, leading to a variety of visual phenomena such as flashing lights, zig‑zag lines, blind spots, and colour changes like xanthopsia.

While occasional, fleeting colour distortion is common in migraineurs, persistent or severe xanthopsia warrants further evaluation because it can signal other ocular or neurological conditions.

Common Causes

Although migraine aura is the most frequent trigger, xanthopsia can stem from many different medical problems. Below are 9 common causes, listed in order of how often they are encountered in clinical practice.

• Migraine with aura – cortical spreading depression affecting colour‑processing neurons.
• Medication side‑effects – especially phosphodiesterase‑5 inhibitors, digitalis, anticholinergics, and some antibiotics (e.g., fluoroquinolones).
• Retinal or macular disease – age‑related macular degeneration, central serous chorioretinopathy, or macular edema.
• Drug‑induced ocular toxicity – long‑term chloroquine/hydroxychloroquine use, tetracycline, or vitamin A excess.
• Systemic metabolic disturbances – severe liver disease, hyperbilirubinemia (jaundice), or carbon monoxide poisoning.
• Neurological lesions – occipital lobe stroke, tumour, or demyelinating plaque (multiple sclerosis) that disrupt visual pathways.
• Infectious or inflammatory eye conditions – uveitis or herpes simplex keratitis.
• Psychiatric or functional visual disturbances – visual snow syndrome or conversion disorder.
• Hereditary retinal dystrophies – such as cone‑rod dystrophy that can alter colour perception.

Associated Symptoms

Visual changes rarely occur in isolation. When xanthopsia appears during a migraine aura, it is often accompanied by other neurological or systemic signs.

• Other aura phenomena – scintillating scotoma, jagged “zig‑zag” lines, flashing lights, or temporary blind spots.
• Headache – throbbing, unilateral pain that may develop 5–60 minutes after the visual aura.
• Nausea or vomiting – common in migraine attacks.
• Photophobia and phonophobia – heightened sensitivity to light and sound.
• Vertigo or dizziness – especially if the aura spreads to vestibular cortex.
• Speech or motor disturbances – rare but possible if aura spreads beyond visual cortex.
• Systemic signs of toxicity – if medication‑related (e.g., confusion, cardiac palpitations).

When to See a Doctor

Most migraine‑related xanthopsia is benign, but certain features should prompt a medical evaluation:

• The yellow tint persists longer than 30 minutes or does not resolve with the aura.
• You experience sudden loss of vision, flashing lights accompanied by a “curtain” effect, or severe headache that is different from your typical migraines.
• Visual changes occur for the first time after age 40 without a known migraine history.
• There are accompanying neurological deficits such as weakness, numbness, slurred speech, or difficulty walking.
• You are taking new medications or have recently changed dosage.
• You have a history of eye disease (e.g., macular degeneration) and notice new colour distortion.
• Symptoms are associated with systemic signs of toxicity (e.g., jaundice, fever, severe abdominal pain).

Diagnosis

Diagnosis is a stepwise process that combines a detailed history, a focused physical exam, and targeted investigations.

1. Clinical History

• Onset, duration, and pattern of visual changes.
• Relationship to headache, menstrual cycle, stress, sleep, diet, and medications.
• Personal or family history of migraine, ocular disease, or neurological disorders.
• Recent exposures (new drugs, chemicals, infections).

2. Neurological & Ophthalmic Examination

• Visual acuity, colour vision testing (Ishihara plates), and visual field assessment.
• Fundoscopic exam to evaluate the retina, optic disc, and macula.
• Assessment for ptosis, pupil asymmetry, or extra‑ocular movement abnormalities.
• Basic neurological exam to rule out focal deficits.

3. Imaging & Laboratory Tests (as indicated)

• MRI of the brain with gadolinium – to exclude occipital infarcts, tumours, or demyelination.
• CT scan – rapid assessment if stroke is suspected.
• Fundus photography or OCT (optical coherence tomography) – detailed retinal imaging.
• Blood work – liver function tests, bilirubin, complete blood count, toxicology screen, and vitamin A levels if drug toxicity is considered.
• Electroretinography (ERG) – when hereditary retinal dystrophy is suspected.

4. Diagnostic Criteria for Migraine Aura (ICHD‑3)

To attribute xanthopsia to migraine aura, the International Classification of Headache Disorders (ICHD‑3) criteria must be met, including:

• At least two attacks fulfilling the following:
• Fully reversible visual symptoms lasting 5–60 minutes.
• At least one symptom spreads gradually over ≥5 minutes.
• Symptoms are not better accounted for by another disorder.

Treatment Options

Treatment can be divided into acute management of the migraine attack, preventive strategies for frequent auras, and specific interventions when an alternate cause is identified.

Acute Migraine Management

• Triptans (e.g., sumatriptan, rizatriptan) – most effective if taken early, before the headache fully develops.
• NSAIDs (e.g., ibuprofen 400‑600 mg, naproxen) – reduce inflammation and pain.
• Anti‑nausea agents (e.g., metoclopramide, prochlorperazine) – help with vomiting and improve medication absorption.
• Ergots (e.g., dihydroergotamine) – second‑line for patients who do not respond to triptans.
• For patients with contraindications to triptans (e.g., cardiovascular disease), CGRP receptor antagonists (ubrogepant, rimegepant) can be used.

Preventive Therapies

• Beta‑blockers (propranolol, metoprolol) – first‑line for chronic migraine.
• Anticonvulsants – topiramate or valproic acid reduce aura frequency.
• Calcium‑channel blockers – verapamil has evidence for aura‑specific prevention.
• CGRP monoclonal antibodies (erenumab, galcanezumab) – highly effective for refractory migraine.
• Daily magnesium (400‑600 mg) and riboflavin (400 mg) supplements have modest preventive benefit.

When an Alternate Cause Is Identified

• Medication‑induced xanthopsia – discontinue or replace the offending drug under physician guidance.
• Retinal disease – treat according to etiology (e.g., anti‑VEGF injections for macular edema, laser therapy for central serous chorioretinopathy).
• Systemic toxicity – address underlying metabolic disturbance (e.g., chelation for carbon monoxide poisoning, liver support for severe jaundice).
• Neurological lesions – surgical, oncologic, or disease‑modifying therapies as appropriate.

Home & Lifestyle Measures

• Maintain a regular sleep‑wake schedule; aim for 7‑9 hours of sleep.
• Identify and avoid personal migraine triggers (certain foods, alcohol, bright flickering lights).
• Stay hydrated – at least 2 L of water per day.
• Practice stress‑reduction techniques (progressive muscle relaxation, mindfulness, yoga).
• Limit caffeine to ≤200 mg per day; avoid abrupt withdrawal.

Prevention Tips

While not every episode can be avoided, these evidence‑based strategies can reduce the frequency and severity of xanthopsia during migraine aura.

• Keep a migraine diary – record trigger exposure, aura characteristics, and medication response.
• Adopt a migraine‑friendly environment – use anti‑glare glasses, dim lighting, and limit screen time during flare‑prone periods.
• Regular aerobic exercise – 30 minutes of moderate activity most days improves vascular health and reduces migraine burden.
• Balanced diet – focus on magnesium‑rich foods (leafy greens, nuts, legumes) and omega‑3 fatty acids (fatty fish).
• Hormonal stability – for women, consider consistent contraceptive regimens if menstrual cycles trigger auras.
• Discuss with your physician the possibility of prophylactic CGRP antibodies if you have ≥4 aura‑related migraines per month despite conventional preventives.
• Review all prescription and over‑the‑counter meds annually; ask your pharmacist about visual side‑effects.
• If you wear contact lenses, ensure they are replaced as scheduled and keep a cleaning routine to avoid corneal irritation that might mimic visual colour changes.

Emergency Warning Signs

Key Take‑aways

Xanthopsia—seeing the world through a yellow filter—can be an unsettling part of a migraine aura. In most cases, it is a benign, reversible phenomenon linked to the altered firing of visual‑cortex neurons. However, persistent colour distortion or accompanying neurological signs may indicate a separate ocular or systemic problem that requires prompt evaluation.

Understanding triggers, adhering to an acute treatment plan, and employing evidence‑based preventive measures can dramatically lower the frequency of these visual disturbances. When in doubt, especially if red‑flag symptoms appear, seek professional medical care without delay.

---

References: Mayo Clinic. “Migraine with aura.”; International Classification of Headache Disorders (ICHD‑3); American Academy of Ophthalmology. “Color Vision Testing.”; CDC. “Carbon Monoxide Poisoning.”; NIH National Library of Medicine. “Hydroxychloroquine ocular toxicity.”; Cleveland Clinic. “Migraine prevention.”; WHO. “Guidelines for the management of headache disorders.”

```